Business Wire

HUAWEI

21.11.2022 12:24:40 CET | Business Wire | Press release

Share
Innovative Design Cuts CO2 Emissions in Data Centers

Huawei’s ability to build more energy-efficient data centers could be an example to others as decarbonization of the construction sector picks up worldwide, according to a company spokesperson.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221121005364/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Andrew Williamson, Vice President of Government Affairs and Economic Advisor, Huawei speaks at the panel. (Photo: Business Wire)

Andrew Williamson, Vice President of Government Affairs and Economic Advisor at Huawei, said “smart” digital infrastructure and buildings are becoming especially common in China’s Guangdong–Hong Kong–Macao Greater Bay Area (GBA).

“The modularization of data center facilities creates new possibilities for fast construction and with a lower carbon footprint,” said Williamson, who stressed that construction times can be reduced to six months from 18 months, thanks to steel prefabricated design.

“This solution uses much less concrete than conventional buildings, and carbon emissions in the construction phase could be offset by more than 90 percent,” he said.

Williamson made the remarks as he addressed a session organized by the Global Alliance for Buildings and Construction (GlobalABC) and German Energy Agency at the Buildings Pavilion during the ongoing 27th Conference of the Parties, or COP27, in Sharm El-Sheikh, Egypt. The session also included speakers from the German Federal Ministry for Economic Affairs and Climate Action (BMWK), the Chinese Academy of Building Research, the World Resources Institute, ICLEI East Asia, Shenzhen Institute of Building Research and JA Solar.

“The process itself is really important to get collaboration in motion in the decarbonization of the buildings sector. Essentially it is about bringing the different actors together, getting them to talk to each other and agree on a shared vision and some targets, and to agree on the actions that need to be implemented to transform the sector,” said Jonathan Duwyn, Head of Buildings and Construction Portfolio at the United Nations Environment Programme.

In terms of building green and eco-friendly campuses, Huawei has adopted rooftop photovoltaics (PVs) for many of its own facilities, including the Huawei Dongguan Southern Factory. It has also consistently increased the use of electricity from renewable energy sources, which rose by 42.3 percent to 300 million kWh in 2021.

In its headquarters in Shenzhen and Dongguan of China’s GBA area, Huawei’s campuses are both fully powered by clean energy. Elsewhere in the country, the Chengdu Research Center was the first of its kind for the company to achieve net-zero carbon operations.

The company has also contributed in the concerted global effort to power COP27 with clean solar energy. Together with its partner Infinity Power, Huawei supplied all string inverters to the 6MW solar project that has lit up the COP27 conference center.

The solar plant is expected to generate up to 11,723 MWh of energy a year. That can power 5,000 homes and reduce 4,000-plus tons of CO2 emissions annually.

“The project will also provide green electricity to Sharm el-Sheikh for years to come,” said Williamson.

About Huawei

Founded in 1987, Huawei is a leading global provider of information and communications technology (ICT) infrastructure and smart devices. We have 195,000 employees and we operate in more than 170 countries and regions, serving more than three billion people around the world.

Our vision and mission is to bring digital to every person, home and organization for a fully connected, intelligent world. To this end, we will work towards ubiquitous connectivity and inclusive network access, laying the foundation for an intelligent world; provide diversified computing power where you need it, when you need it, to bring cloud and intelligence to all four corners of the earth; build digital platforms to help all industries and organizations become more agile, efficient, and dynamic; and redefine user experience with AI, making it smarter and more personalized for people in all aspects of their life, whether they're at home, on the go, in the office, having fun, or working out. For more information, please visit Huawei online at www.huawei.com or follow us on:

http://www.linkedin.com/company/Huawei
http://www.twitter.com/Huawei
http://www.facebook.com/Huawei
http://www.youtube.com/Huawei

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221121005364/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release

The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye